Bicocca Open Archive

Logo unimib boa
CORTESI, PAOLO ANGELO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.977
AS - Asia 13.026
EU - Europa 10.504
SA - Sud America 1.832
Continente sconosciuto - Info sul continente non disponibili 1.339
AF - Africa 338
OC - Oceania 57
Totale 50.073
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.642
SG - Singapore 4.795
IT - Italia 3.806
CN - Cina 2.441
VN - Vietnam 1.705
HK - Hong Kong 1.682
BR - Brasile 1.344
RU - Federazione Russa 1.292
DE - Germania 1.156
CA - Canada 1.039
SE - Svezia 738
IE - Irlanda 685
FR - Francia 580
GB - Regno Unito 535
BD - Bangladesh 514
IN - India 430
UA - Ucraina 416
FI - Finlandia 277
ID - Indonesia 244
NL - Olanda 199
TR - Turchia 183
AR - Argentina 175
DK - Danimarca 155
KR - Corea 154
AT - Austria 148
IQ - Iraq 126
MX - Messico 122
ES - Italia 113
ZA - Sudafrica 106
PK - Pakistan 100
JP - Giappone 81
PH - Filippine 76
PL - Polonia 76
SA - Arabia Saudita 75
EC - Ecuador 74
CH - Svizzera 71
CO - Colombia 62
VE - Venezuela 57
BE - Belgio 52
IR - Iran 50
UZ - Uzbekistan 48
AU - Australia 47
CL - Cile 44
JM - Giamaica 41
MA - Marocco 39
MY - Malesia 38
AE - Emirati Arabi Uniti 37
TH - Thailandia 37
KE - Kenya 33
EG - Egitto 32
ET - Etiopia 28
CR - Costa Rica 26
NP - Nepal 25
CZ - Repubblica Ceca 24
JO - Giordania 24
TN - Tunisia 24
PT - Portogallo 23
PY - Paraguay 23
PE - Perù 22
RO - Romania 22
TW - Taiwan 22
DZ - Algeria 19
TT - Trinidad e Tobago 19
LT - Lituania 18
AL - Albania 17
BG - Bulgaria 17
GT - Guatemala 17
BO - Bolivia 16
IL - Israele 15
GR - Grecia 14
KG - Kirghizistan 13
OM - Oman 13
DO - Repubblica Dominicana 12
HN - Honduras 12
LB - Libano 12
NI - Nicaragua 12
AZ - Azerbaigian 11
EU - Europa 11
NO - Norvegia 11
LK - Sri Lanka 10
UY - Uruguay 10
MN - Mongolia 9
NG - Nigeria 9
KZ - Kazakistan 8
MD - Moldavia 8
RS - Serbia 8
BH - Bahrain 7
BY - Bielorussia 7
NZ - Nuova Zelanda 7
SI - Slovenia 7
BB - Barbados 6
HR - Croazia 6
KW - Kuwait 6
PS - Palestinian Territory 6
SK - Slovacchia (Repubblica Slovacca) 6
SN - Senegal 6
BZ - Belize 5
GA - Gabon 5
HU - Ungheria 5
GE - Georgia 4
Totale 48.639
Salva come PNG Salva come JPEG
Città #
Singapore 2.351
Ashburn 2.336
Ann Arbor 1.847
San Jose 1.783
Hong Kong 1.651
Milan 1.112
Fairfield 859
Woodbridge 834
Chandler 728
Houston 725
Toronto 723
Frankfurt am Main 659
Dublin 655
New York 603
Council Bluffs 594
Wilmington 570
Santa Clara 555
Ho Chi Minh City 513
Hanoi 433
Los Angeles 427
Seattle 410
Dallas 406
Jacksonville 391
Chicago 348
Dearborn 345
Beijing 332
The Dalles 298
Rome 290
Princeton 283
Cambridge 280
Hefei 245
Lauterbourg 170
Jakarta 160
Columbus 157
Boardman 156
Helsinki 146
Nanjing 146
Buffalo 144
São Paulo 134
Seoul 130
Altamura 128
Lawrence 124
Orem 114
Phoenix 111
Vienna 108
Moscow 107
Shanghai 104
Munich 91
London 87
Denver 79
Guangzhou 79
Atlanta 73
Naples 73
San Diego 73
Brooklyn 66
Da Nang 66
San Francisco 66
Tokyo 65
Figino 61
Haiphong 61
Montreal 61
Lachine 60
Nuremberg 58
Bologna 55
Washington 55
Turin 54
Warsaw 54
Boston 53
Rio de Janeiro 53
Andover 51
Baghdad 49
Chennai 49
Hangzhou 49
Nanchang 48
Johannesburg 47
Shenyang 47
Philadelphia 45
Lappeenranta 44
Dong Ket 43
Tianjin 43
Zurich 42
Amsterdam 40
Florence 39
Ottawa 39
Paris 39
Tashkent 38
Austin 37
Brasília 36
Mexico City 36
Mumbai 36
Dhaka 35
Poplar 35
Brussels 34
Fremont 34
Jinan 34
Changsha 33
Verona 33
Can Tho 32
Istanbul 32
Lissone 32
Totale 28.399
Salva come PNG Salva come JPEG
Nome #
Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 663
Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 628
Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023 609
Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023 606
Costs and effects of cardiovascular risk reclassification using the ankle-brachial index (ABI) in addition to the Framingham risk scoring in women 497
Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology 482
Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 477
Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review 458
State of health and inequalities among Italian regions from 2000 to 2021: a systematic analysis based on the Global Burden of Disease Study 2021 454
Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors 453
Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021 442
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine 408
Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis 403
Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017 402
Trends in cardiovascular diseases burden and vascular risk factors in Italy: The Global Burden of Disease study 1990–2017 400
Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 397
Value-based outcome indicators in the management of hepatocellular carcinoma: Clinical test in a large multicenter study (VBMH study) 379
Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 377
Use of health care administrative databases to estimate the burden of multiple sclerosis: a population-based study 368
Use of health care administrative databases to estimate the burden of breast cancer. 368
Liver Transplantation in Alcohol-Associated Hepatitis. Benefits and Limitations of Psychosocial Selection and Support in Alcohol Relapse. The Experience of a Tertiary Center in Italy 361
Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context 357
Health related quality of life in chronic liver diseases 356
Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 347
The socioeconomic burden of patients affected by hemophilia with inhibitors 343
Italy's health performance, 1990–2017: findings from the Global Burden of Disease Study 2017 343
Trattamento con Sofosbuvir e Ribavirina nei pazienti hcv-positivi listati per il trapianto di fegato: un analisi di costo-efficacia 341
Health Related Quality of Life in the Major Liver Conditions 340
Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017 337
Costs and effectiveness of influenza vaccination: A systematic review 336
Generation and performance of value-based outcome indicators in liver disease: The multicenter V.B.M.H. study 335
Outcome indicators in liver cirrhosis: Application of value-based medicine in a large multicenter study (VBMH study) 332
Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: A systematic analysis for the Global Burden of Disease Study 2017 331
The impact of liver disease on the health-related quality of life 327
Outcome Indicators in Primary Sclerosing Cholangitis: Interim Analysis Of The Value-Based Medicine In Hepatology (VBMH) Study 324
P1169 : Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 322
Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 319
Global, regional, and national burden of congenital heart disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 318
Generation and Performance of Outcome Indicators in Liver Cirrhosis: The Value Based Medicine in Hepatology Study (V.B.M.H.) 309
Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis 309
P0811 : Sofosbuvir-based direct-acting antivirals treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 308
Azithromycin use and outcomes in patients with COVID-19: an observational real-world study 307
Value-based outcome indicators in liver cirrhosis: validation in a large multicenter study (VBMH study) 307
Measurement of clinical outcomes and quality of life indicators as a new value-based approach to liver cirrhosis management 306
Characteristics of patients with Chronic Hepatitis C who have failed past treatment or who have never been treated: How much room left for Interferon? 305
A Comparison Between The Health-Related Quality Of Life Reported By The General Population And By Patients With Major Liver Diseases 305
Global, regional, and national burden of epilepsy, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 302
Time-Trends in Air Pollution Impact on Health in Italy, 1990–2019: An Analysis From the Global Burden of Disease Study 2019 302
Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016 302
Impatto dei farmaci anti virali ad azione diretta sulla cura dei pazienti con epatite C: un approccio di value-based medicine 300
The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities 296
A value-based approach to the management of patients with liver cirrhosis through the systematic measurement of clinical outcome and quality of life indicators 295
Difference in health related quality of life of chronic liver diseases and general population 294
Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors 294
Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017 293
The Impact of Type of Liver Conditions on the Patients’ Health Related Quality of Life 292
Benefits in pain perception, ability function and health-related quality of life in patients with failed back surgery syndrome undergoing spinal cord stimulation in a clinical practice setting 292
Sustainability of the Italian National Health Service 287
2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation 282
Value-based approach to hepatocellular carcinoma: outcome indicators tested in a large multicenter study (VBMH study) 280
Generalizability and treatment with sodium-glucose co-trasporter-2 inhibitors (SGLT2i) among patients with type 2 diabetes: an assessment using an Italian primary care database 279
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 279
Immune tolerance induction in patients with haemophilia a and inhibitors: Effectiveness and cost analysis in an European Cohort (The ITER Study) 278
Modern Treatments of Haemophilia: Review of Cost-Effectiveness Analyses and Future Directions 277
COVID-19 outbreak impact on anticoagulants utilization: an interrupted time-series analysis using healthcare administrative databases 276
Treatment patterns in essential tremor: Real-world evidence from a United Kingdom and France primary care database 275
Models of The Impact of Major Liver Diseases on Eq-5d Visual Analogue Scale and Utility-Index: Convergences and Divergences 274
Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: results of the ELITA/EF-CLIF collaborative study (ECLIS) 274
Management of treatment-naïve chronic hepatitis C genotype 1 patients: A cost-effectiveness analysis of treatment options 272
Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era 269
Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: An Updated Systematic Literature Review 267
Applicazione della value-based medicine nella valutazione della cura dei pazienti affetti da epatite. 267
Sofosbuvir-based all-oral treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 266
Health related quality of life norm data of the general population in Italy: Results using the EQ-5D-3L and EQ-5D-5L instruments 265
The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 265
Should Sofosbuvir-Based All-Oral Treatment Be Considered In Elderly Chronic Hepatitis C Patients? 264
Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: An extension of the Psoriatic Arthritis Cost Evaluation (PACE) study 263
Meta-analysis on incidence of inhibitors in patients with haemophilia A treated with recombinant factor VIII products 263
Should new antiviral treatments be considered in elderly Chronic Hepatitis C patients? 261
Il carico di malattia associato ai virus dell'epatite B e C in Europa. Dati dal Global Burden of Disease Study 2019 260
PGI31 Health Care Indicators to Measure Quality of Care in Patients with Liver Diseases 260
Preferenze della popolazione italiana per gli stati di salute dell'EQ-5D 260
Incidence of inhibitors to recombinant factor VIII products – A meta-analysis of 1,852 previously untreated patients 256
Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 254
Haemophilia management and treatment: An Italian survey on patients’, caregivers’ and clinicians’ point of view 254
Protective role of tacrolimus, deleterious role of age and comorbidities in liver transplant recipients with Covid-19: results from the ELITA/ELTR multi-center European study 249
Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study 249
A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy 249
The value‐based healthcare approach to haemophilia: Development of outcome measures for the evaluation of care of people with haemophilia 247
PGI36 Relationship Between Clinical Severity and Health Related Quality of Life in Chronic Liver Diseases 244
Economic Burden of Urticaria Requiring Hospitalization: Analysis from an Administrative Database 243
Antidepressants Drug Use during COVID-19 Waves in the Tuscan General Population: An Interrupted Time-Series Analysis 243
The Burden of Severe Hypoglicaemias and Diabetes Ketoacidosis: A Population-Based Study 242
The Cost-Effectiveness Of Sofosbuvir And Ribavirin Treatment In Hcv-Infected Patients Listed For Liver Transplantation 241
Economic Burden Of Stroke: Analysis From An Administrative Database 241
Patients’, physicians’, nurses’, and pharmacists’ preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases 241
The psychosocial impact of haemophilia from patients’ and caregivers’ point of view: The results of an Italian survey 240
Il burden delle polmoniti: analisi dai database amministrativi (DENALI) della regione Lombardia. 238
Italian population-based values of EQ-5D health states 238
Utilization of disease modifying agents in multiple sclerosis: from an Italian administrative database. 237
Totale 32.227
Salva come PNG Salva come JPEG
Categoria #
all - tutte 161.225
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 161.225
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.296 0 0 0 178 130 146 64 121 109 129 106 313
2022/20233.149 327 896 275 271 212 452 57 195 222 49 100 93
2023/20242.707 98 119 93 149 295 645 397 119 233 114 140 305
2024/20257.658 350 712 354 361 607 467 442 292 791 920 1.007 1.355
2025/202619.463 2.093 1.029 1.183 1.788 2.057 1.047 2.607 794 1.432 1.943 1.553 1.937
2026/20275.708 879 1.262 2.816 751 0 0 0 0 0 0 0 0
Totale 50.073